Subcellular distribution of envoplakin and periplakin: insights into their role as precursors of the epidermal cornified envelope.
Envoplakin and periplakin are two plakins that are precursors of the epidermal cornified envelope. We studied their distribution and interactions by transfection of primary human keratinocytes and other cells. Full-length periplakin localized to desmosomes, the interdesmosomal plasma membrane and intermediate filaments. Full length envoplakin also localized to desmosomes, but mainly accumulated in nuclear and cytoplasmic aggregates with associated intermediate filaments. The envoplakin rod domain was required for aggregation and the periplakin rod domain was necessary and sufficient to redistribute envoplakin to desmosomes and the cytoskeleton, confirming earlier predictions that the proteins can heterodimerize. The linker domain of each protein was required for intermediate filament association. Like the NH(2) terminus of desmoplakin, that of periplakin localized to desmosomes; however, in addition, the periplakin NH(2) terminus accumulated at cell surface microvilli in association with cortical actin. Endogenous periplakin was redistributed from microvilli when keratinocytes were treated with the actin disrupting drug Latrunculin B. We propose that whereas envoplakin and periplakin can localize independently to desmosomes, the distribution of envoplakin at the interdesmosomal plasma membrane depends on heterodimerization with periplakin and that the NH(2) terminus of periplakin therefore plays a key role in forming the scaffold on which the cornified envelope is assembled.
DiColandrea
T
T
Keratinocyte Laboratory, Imperial Cancer Research Fund, London WC2A 3PX, England.
Karashima
T
T
Määttä
A
A
Watt
F M
FM
D000199:Actins / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D002467:Cell Nucleus / Q000378:metabolism; D002478:Cells, Cultured; D003593:Cytoplasm / Q000378:metabolism; D003598:Cytoskeletal Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D003599:Cytoskeleton / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D003896:Desmosomes / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D019281:Dimerization; D000078404:Epidermal Cells; D004817:Epidermis / Q000187:drug effects / Q000254:growth & development* / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D007633:Keratins / Q000378:metabolism; D008565:Membrane Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008854:Microscopy, Electron; D051179:Plakins; D011485:Protein Binding; D011498:Protein Precursors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D017434:Protein Structure, Tertiary; D012995:Solubility; D013844:Thiazoles / Q000494:pharmacology; D053778:Thiazolidines; D014162:Transfection
D000199:Actins; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003598:Cytoskeletal Proteins; D008565:Membrane Proteins; C491674:PPL protein, human; D051179:Plakins; C110037:Ppl protein, mouse; D011498:Protein Precursors; D013844:Thiazoles; D053778:Thiazolidines; C100754:envoplakin; D007633:Keratins; C037068:latrunculin B